The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin‐diabetic rats
Open accessAbstract
Fibrosis leads to chronic impairment of cardiac and renal function and thus reversal of existing fibrosis may improve function and survival. This project has determined whether pirfenidone, a new antifibrotic compound, and spironolactone, an aldosterone antagonist, reverse both deposition of the major extracellular matrix proteins, collagen and fibronectin, and functional changes in the streptozotocin(STZ)‐diabetic rat. Streptozotocin (65 mg kg−1 i.v.)‐treated rats given pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone; approximately 200 mg kg−1 day−1 as 0.2–2g 1−1 drinking water) or spironolactone (50 mg kg−1 day−1 s.c.) for 4 weeks starting 4 weeks after STZ showed no attenuation of the increased blood glucose concentrations and increased food and water intakes which characterize diabetes in this model. STZ‐treatment increased perivascular and interstitial collagen deposition in the left ventricle and kidney, and surrounding the aorta. Cardiac, renal and plasma fibronectin concentrations increased in STZ‐diabetic rats. Passive diastolic stiffness increased in isolated hearts from STZ‐diabetic rats. Both pirfenidone and spironolactone treatment attenuated these increases without normalizing the decreased +dP/dt max of STZ‐diabetic hearts. Left ventricular papillary muscles from STZ‐treated rats showed decreased maximal positive inotropic responses to noradrenaline, EMD 57033 (calcium sensitizer) and calcium chloride; this was not reversed by pirfenidone or spironolactone treatment. STZ‐treatment transiently decreased GFR and urine flow rates in isolated perfused kidneys; pirfenidone but not spironolactone prevented the return to control values. Thus, short‐term pirfenidone and spironolactone treatment reversed cardiac and renal fibrosis and attenuated the increased diastolic stiffness without normalizing cardiac contractility or renal function in STZ‐diabetic rats. British Journal of Pharmacology (2001) 133, 687–694; doi:10.1038/sj.bjp.0704131
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Cited by
Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications
Fang, Z. Y., Prins, J. B., & Marwick, T. H. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0012 · Cited by 912
Mechanisms of Tubulointerstitial Fibrosis
Zeisberg, M., & Neilson, E. G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080793 · Cited by 868
The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic Cardiomyopathy
Asbun, J., & Villarreal, F. J. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.050 · Cited by 486
Russo, I., & Frangogiannis, N. G. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.011 · Cited by 474
NOGUEIRA, A., PIRES, M. J., & OLIVEIRA, P. A. (2017) · In Vivo · doi:10.21873/invivo.11019 · Cited by 382
Metadata
- Authors
- Miric, G., Dallemagne, C., Endre, Z., Margolin, S., Taylor, S. M., & Brown, L.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2001-07
- Volume
- 133
- Issue
- 5
- Pages
- 687-694
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2067789393
- Cited by
- 210
- References
- 1
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin‐diabetic rats. https://app.cochat.ai/papers/10.1038/sj.bjp.0704131
- The paper
- Miric, G., Dallemagne, C., Endre, Z., Margolin, S., Taylor, S. M., & Brown, L. (2001). Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin‐diabetic rats. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0704131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.